Table 1.
Clinical, pathological characteristics and response to EGFR TKIs of patients with tumors harboring EGFR exon 19 insertion mutations: K745_E746insIPVAIK and others.
| Case number | Ref. (number) | EGFR mutation/histology | EGFR TKI (line of therapy) | Dose | Response RECI ST | Percent change target lesion(s) | PFS (months) | OS(months from start of EGFR TKI) | sex/age(years)/ethnicity/PS | smoking history (pack-years) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 25 | I740_K745dupI PVAIK*/adenocarcinoma | Icotinib (1st) | NA | PR | NA | 13 | NA | M/74/Asian/NA | NA |
| 2 | 31 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | 250 mg | PR | − 43.7% | 4 | 10 | M/68/Asian/NA | 50 |
| 3 | 31 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | 250 mg | SD | NA | 5 | NA | F/51/Asian/NA | 0 |
| 4 | 33 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | NA | PR | NA | 5 | 9 | F/42/Asian/NA | 0 |
| 5 | 36 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | 250 mg | PR | -70% | 5 | NA | F/56/white/NA | 0 |
| 6 | 36 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (2nd) | 250 mg | SD | NA | >9 | NA | F/48/white/NA | 0 |
| 7 | 36 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | 250 mg | SD | NA | >11 | NA | F/54/white/NA | 0 |
| 8 | 27 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | 250 mg | PR | NA | 12 | 18 | F/48/white/2 | 0 |
| 9 | 33 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (2nd) | NA | SD | NA | 22 | 32 | M/46/Asian/NA | 15 |
| 10 | 37 | I744_K745insKIPVAI*/adenocarcinoma | Gefitinib (1st) | NA | SD | NA | 24 | NA | F/37/Asian/NA | 0 |
| 11 | 33 | I744_K745insKIPVAI*/adenocarcinoma | Erlotinib (2nd) | NA | PD | NA | 2 | 11 | F/47/Asian/NA | 0 |
| 12 | 26 | delI744_K745in sKIPVAI*/adenocarcinoma | Erlotinib (2nd) | 150 mg | PR | NA | 7 | 9 | F/36/white/NA | NA |
| 13 | current BIDM C | K739_I744dup KIPVAI*/adenocarcinoma | Erlotinib (1st) | 150 mg | PR | − 30.4% | 7 | 11 | F/59/white/3 | 0 |
| 14 | current BIDM C | K739_I744dup KIPVAI*/adenocarcinoma | Erlotinib (2nd) | 100 mg | PR | − 31.2% | 8 | 12 | F/68/white/0 | 10 |
| 15 | 34 | K745_E746insI PVAIK/adenocarcinoma | Erlotinib (1st) | 150 mg | PR | NA | 9 | NA | F/39/Arab/3 | 0 |
| 16 | 37 | E746_L747insV PVAIK/adenocarcinoma | Erlotinib (1st) | NA | PR | NA | 16 | NA | F/60/Asian/NA | 0 |
| 17 | 29 | I740_K745dupI PVAIK*/adenocarcinoma | Erlotinib (3rd) | 150 mg | PR | NA | 16 | >48 | F/39/white/NA | 0 |
| 18 | 28 | K745_E746insI PVAIK/adenocarcinoma | Erlotinib (1st) | 150 mg | SD | NA | 18 | 24 | F/55/Asian/1 | 0 |
| 19 | 19 | K745_E746ins PVAIK/adenocarcinoma | Erlotinib (1st) | NA | PR | NA | 19 | NA | NA | NA |
| 20 | 19 | K745_E746insIPVAIK/adenocarcinoma | Erlotinib (1st) | NA | PR | NA | 50 | NA | NA | NA |
| 21 | 35 | K745_E746insIPVAIK/adenocarcinoma | Afatinib (1st) | 40 mg | PD | NA | 1 | 4 | F/75/Asian/1 | NA |
| 22 | 30 | I740_K745dupIPVAIK*/adenocarcinoma | Afatinib (2nd) | 30 mg | PR | NA | 13 | 21 | M/63/Asian/NA | 45 |
| 23 | 19 | K745_E746insI PVAIK/adenocarcinoma | Afatinib (1st) | NA | PR | NA | 14 | NA | NA | NA |
| 24 | 38 | I740_K745dupI PVAIK*/NSCLC NOS | Osimertinib (1st)+bevacizumab | NA | PR | NA | >1 | NA | F/58/Asian/NA | NA |
| 25 | 38 | I740_K745dupI PVAIK*/NSCLC NOS | Osimertinib (1st) | NA | PR | NA | >2 | NA | F/67/Asian/NA | 0 |
| 26 | current BIDM C | K745_E746insI PVAIK/adenocarcinoma | Osimertinib (1st) | 80 mg | PR | − 31.6% | 9 | >13 | F/73/white/0 | 2 |
EGFR, epidermal growth factor receptor; PS, ECOG performance status; TKI, tyrosine kinase inhibitor; RECIST, Response evaluation in solid tumors version 1.1; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; NSCLC NOS, non-small-cell lung cancer not otherwise specified; NA, not available; +, ongoing survival for PFS or OS. For OS, it was assumed survival was ongoing (>) when report did not specify otherwise. When extrapolating from written or graphic data from publications, we rounded response change or months to nearest full value. * indicates mutations that have the same amino-acid sequence as EGFR-K745_E746insIPVAIK